Compare SkyWest Inc (SKYW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SkyWest Inc vs TG Therapeutics Inc — how do they compare? SkyWest Inc trades at $96.57 (market cap $3.75B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 2.2× SkyWest Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SkyWest Inc for 8 Days and TG Therapeutics Inc for 16 Days on average.
| SKYW | TGTX | |
|---|---|---|
Market Cap | $3.75B | $8.16B |
Volume | 196,324 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $115.94 | $59.06 |
52-Week Low | $78.40 | $26.94 |
Typical Hold Time | 8 Days | 16 Days |
Enterprise Value | $5.54B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SkyWest (SKYW) trades at $96.64, down 1.1% on the day, with a bearish technical signal from moving averages. The stock shows attractive valuation metrics, including a P/E of 9.6 and P/S of 0.94, while maintaining solid profitability with a 9.78% net income margin. Recent earnings have been mixed, with a Q1 2026 beat but a Q2 2026 miss. Positive developments include fleet modernization efforts and expanded flying agreements, though cost pressures remain a concern.
The investment case balances strong analyst support—58.82% recommend Buy with a $112 consensus target—against near-term technical weakness and earnings volatility. Upside potential exists from operational improvements and cash flow growth, but risks include execution on cost management and broader airline industry challenges. The stock presents a value opportunity for patient investors despite current bearish momentum.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
